A pharmaceutical company is developing a novel Janus kinase (JAK) inhibitor for the treatment of severe, refractory rheumatoid arthritis. Regulatory guidelines stipulate that the manufacturer must conduct two independent, pivotal Phase III randomized controlled trials demonstrating efficacy. The research team designs Trial X with a statistical power of 80% and Trial Y with a statistical power of 90% to detect the predefined minimum clinically important difference. Both trials use a two-sided alpha level of 0.05.
Assuming the new JAK inhibitor is genuinely effective at or above the minimum clinically important difference, what is the probability (expressed as a percentage) that BOTH trials will fail to yield statistically significant results?
Cevap: 2 %